ASCVD Risk Estimator (SCORE2 / Framingham)
10-year risk assessment for atherosclerotic cardiovascular disease (MI, Stroke).
The ASCVD Risk Estimator: Cardiovascular Prevention
The ASCVD (Atherosclerotic Cardiovascular Disease) risk calculator, derived from the ACC/AHA guidelines, is the global reference tool (along with its European equivalent SCORE2) for assessing overall cardiovascular risk. It estimates the 10-year probability of a patient developing a major cardiovascular event (fatal or non-fatal myocardial infarction, stroke).
When to use this tool in clinical practice?
This tool is designed for primary prevention. It should not be used in patients who already have a history of atherosclerotic cardiovascular disease. The ASCVD score helps the physician decide on the necessity of initiating preventive treatment:
- Statin Therapy: Recommended if the 10-year risk is ≥ 7.5% (and strongly recommended if ≥ 20%).
- Aspirin for primary prevention: Discussed on a case-by-case basis for high risks, although recent guidelines are more restrictive.
- Blood pressure management: A high risk prompts targeting stricter blood pressure goals (often < 130/80 mmHg).
Limitations and Shared Decision Making
The calculation is merely a statistical estimate. Therapeutic decisions must involve "shared decision-making" with the patient. Risk Enhancing Factors such as a family history of premature coronary disease or a high coronary artery calcium (CAC) score can tip the balance toward treatment even if the score is in the borderline zone (5 - 7.4%).
10-Year Risk Interpretation
| 10-Year Risk | Category | Recommended Action (Statin) |
|---|---|---|
| < 5.0 % | Low Risk | Lifestyle modifications |
| 5.0 - 7.4 % | Borderline Risk | Risk discussion with patient |
| 7.5 - 19.9 % | Intermediate Risk | Moderate-intensity statin |
| ≥ 20.0 % | High Risk | High-intensity statin |
References:
1. Goff DC Jr, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49-73.
[AHA Journals]
2. Arnett DK, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019;140(11):e596-e646.
[ACC/AHA Guidelines]
-
💡 Committed to scientific accuracy, if you notice any clinical or technical discrepancy, please let us know.